 HOUSTON, Feb. 16, 2021 GLOBE NEWSWIRE -- Bio-Path Holdings, Inc., Nasdaq:BPTH, a biotechnology company leveraging its proprietary DNAbilize liposomal delivery and antisense technology to develop a portfolio of targeted nucleic acid cancer drugs, today announced the pricing of its previously announced public offering for the offering of 1,710,600 shares of common stock at a price to the public of 7.60 per share, for aggregate gross proceeds to the Company of approximately 13.0 million, before deducting the fees and estimated offering expenses payable by the Company. The offering is expected to close on or about February 18, 2021, subject to customary closing conditions. 